| 94.43 Delayed Data As of 4:00pm ET |  -0.84 / -0.88%Today’s Change | 68.56 Today|||52-Week Range 96.57 | +31.08% Year-to-Date |
| Can Zoetis (ZTS) Stock Continue to Grow Earnings? 9:42am / Zacks.com - Paid Partner Content | Zoetis (ZTS) Q3 Earnings & Revenues Surpass Estimates Nov 01 / Zacks.com - Paid Partner Content |
| Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View Nov 01 / Zacks.com - Paid Partner Content | Should You Buy Zoetis (ZTS) Ahead of Earnings? Oct 31 / Zacks.com - Paid Partner Content |
| Zoetis (ZTS) Tops Q3 Earnings and Revenue Estimates Nov 01 / Zacks.com - Paid Partner Content |
| Previous close | 95.27 |
| Today’s open | 95.18 |
| Day’s range | 94.14 - 95.57 |
| Volume | 2,120,790 |
| Average volume (3 months) | 2,325,836 |
| Market cap | $45.8B |
| Earnings growth (last year) | +6.02% |
| Earnings growth (this year) | +29.57% |
| Earnings growth (next 5 years) | +15.30% |
| Revenue growth (last year) | +8.57% |
| P/E ratio | 39.7 |
| Price/Sales | 6.69 |
| Price/Book | 26.17 |
| Today’s change | Today’s % change | |
|---|---|---|
| VRTXVertex Pharmaceutica... | -7.70 | -4.26% |
| CELGCelgene | -2.87 | -3.88% |
| REGNRegeneron Pharmaceut... | -10.10 | -2.83% |
| SHPGShire | +1.64 | +0.91% |
| Next reporting date | February 12, 2019 |
| EPS forecast (this quarter) | $0.77 |
| Annual revenue (last year) | $5.3B |
| Annual profit (last year) | $864.0M |
| Net profit margin | 16.28% |
Sector Health Technology |
Industry Pharmaceuticals: Generic |
Chief Executive Officer & Director Juan Ramón Alaix |
Executive Vice President & President-US Operations Kristin C. Peck |
Corporate headquarters New Jersey, New Jersey |
